论文部分内容阅读
目的探究吉西他滨联合顺铂治疗晚期乳腺癌的临床效果及不良反应,为今后的临床工作提供参考依据。方法选取2009年1月至2011年1月在湖南省肿瘤医院进行乳腺癌治疗的80例乳腺癌患者为研究对象,按照治疗方式的不同,分为对照组与观察组,每组40例。对照组给予长春瑞滨联合顺铂治疗,观察组给予吉西他滨联合顺铂治疗,观察两组患者的临床疗效及不良反应。结果两组患者经治疗后的总有效率比较,差异无统计学意义(χ2=0.0494,P=0.8241);两组患者治疗后的不良反应情况:静脉炎比较,差异有统计学意义(χ2=15.3284,P=0.0001);白细胞减少比较,差异无统计学意义(χ2=1.8441,P=0.1745);血小板减少比较,差异无统计学意义(χ2=0.0638,P=0.8006);胃肠反应比较,差异无统计学意义(χ2=0.8163,P=0.3663)。结论吉西他滨联合顺铂治疗晚期乳腺癌疗效显著,同时能减少患者治疗期间的不良反应,值得临床推广使用。
Objective To investigate the clinical effects and adverse reactions of gemcitabine plus cisplatin in the treatment of advanced breast cancer and provide reference for future clinical work. Methods Eighty patients with breast cancer who underwent treatment of breast cancer at Hunan Cancer Hospital from January 2009 to January 2011 were selected as study subjects and divided into control group and observation group with 40 cases in each group according to different treatment methods. The control group was treated with vinorelbine plus cisplatin. The observation group was treated with gemcitabine plus cisplatin. The clinical efficacy and adverse reactions of the two groups were observed. Results There was no significant difference in the total effective rate between the two groups after treatment (χ2 = 0.0494, P = 0.8241). Adverse reactions after treatment in both groups: phlebitis, the difference was statistically significant (χ2 = (Χ2 = 1.8441, P = 0.1745); thrombocytopenia, the difference was not statistically significant (χ2 = 0.0638, P = 0.8006); gastrointestinal reactions compared, The difference was not statistically significant (χ2 = 0.8163, P = 0.3663). Conclusion Gemcitabine combined with cisplatin in the treatment of advanced breast cancer has obvious curative effect, meanwhile it can reduce the adverse reactions during the treatment of patients and is worthy of clinical promotion.